GlassScriptPhysician profile
Gabriela Cuevas
NPI 1255955035
$3,687.50
in general payments reported to CMS, 2019-2025
17 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $326 · 2022: $1,204 · 2023: $1,393 · 2024: $423 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $1.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.22 |
| Education | $1.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,115.39 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $585.09 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $394.05 | 2022-2023 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $278.43 | 2021-2024 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $215.40 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $176.97 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $129.29 | 2022-2024 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $127.22 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $124.34 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $113.04 | 2022-2023 | Austedo Xr |
| Eisai INC. | $110.42 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.33 | 2022 | |
| Vanda Pharmaceuticals INC. | $76.06 | 2021-2022 | |
| Novo Nordisk INC | $68.54 | 2022 | |
| Idorsia Pharmaceuticals US INC | $40.68 | 2022-2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $38.94 | 2023-2025 | Lybalvi, Aristada |
| Vistapharm, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriela Cuevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.